These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38943449)

  • 1. Functional combination of resveratrol and tamoxifen to overcome tamoxifen-resistance in breast cancer cells.
    Radwan AM; Abosharaf HA; Sharaky M; Abdelmonem R; Effat H
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400261. PubMed ID: 38943449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
    Han X; Li Q; Liu C; Wang C; Li Y
    J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
    Shi YF; Lu H; Wang HB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
    Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
    Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone-tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells.
    Gaballah AI; Elsherbiny AA; Sharaky M; Hamed NO; Raslan NA; Almilaibary A; Fayyad RMA; Ousman MS; Hamdan AME; Fahim SA
    Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38864530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α.
    Attia YM; Mokhlis HA; Ismail A; Doghish AS; Sobhy MH; Hassanein SS; El-Dakroury WA; Mariee AD; Salama SA; Sharaky M
    Med Oncol; 2024 Aug; 41(9):232. PubMed ID: 39167288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corylin sensitizes breast cancer cells to overcome tamoxifen resistance by regulating OAS1/miR-22-3p/SIRT1 axis.
    Che L; Yang H; Wang D; Liu S
    Acta Biochim Pol; 2021 Nov; 68(4):757-764. PubMed ID: 34731560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer.
    Guney Eskiler G; Cecener G; Dikmen G; Egeli U; Tunca B
    Eur J Pharm Sci; 2018 Jul; 120():73-88. PubMed ID: 29719240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J; Lu M; Jin J; Lu X; Xu T; Jin S
    Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
    Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
    Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
    Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.
    Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE
    Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
    Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
    Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell.
    Lee S; Lee H; Jeong D; Ham J; Park S; Choi EH; Kim SJ
    Free Radic Biol Med; 2017 Sep; 110():280-290. PubMed ID: 28666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA-128 and miRNA-223 regulate cholesterol-mediated drug resistance in breast cancer.
    Palma GBH; Kaur M
    IUBMB Life; 2023 Sep; 75(9):743-764. PubMed ID: 37070323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.